[Indication for haemoderivatives in dengue].
Management of patients with dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) requires especial care. It is based on physiological replacement therapy and fluid control. The use of blood products has its own criteria, especially during the disseminated intravascular coagulation (DIC) in the hemorrhagic phase. Monitoring bleeding manifestations and laboratory tests are needed. It has been shown that preventive transfusion does not have advantages in the treatment of this disease; on the contrary it increases the length of hospitalization and the development of pulmonary edema, among other transfusion-related risks.
Larreal
Yraima
Y
D016913:Blood Component Transfusion; D006801:Humans; D019595:Severe Dengue / Q000628:therapy*
Indicación de hemoderivados en dengue.